Table 1.
Baseline Characteristics and Predictors of Loss to Follow-up at 6 Months Among People with Newly Diagnosed Human Immunodeficiency Virus in Eastern Ethiopia, 2020–2021 (N = 235)
| Characteristic | Total No. (%)a | LTFU at 6 mo, No. (%)a | Bivariable Analysis | Multivariable Analysis | |||
|---|---|---|---|---|---|---|---|
| Yes | No | COR (95% CI) | P Value | AOR (95% CI) | P Value | ||
| Sex | |||||||
| Male | 69 (29.4) | 9 (13.1) | 60 (86.9) | 1.00 | … | … | … |
| Female | 166 (70.6) | 30 (18.1) | 136 (81.9) | 1.47 (.65–3.28) | .35 | … | … |
| Age group, y | |||||||
| ≤24 | 50 (21.3) | 11 (22.0) | 39 (78.0) | 1.58 (.72–3.45) | .25 | 1.87 (.77–4.51) | .16 |
| >24 | 185 (78.7) | 28 (15.1) | 157 (84.9) | 1.00 | … | … | >.99 |
| Health facility type | |||||||
| Hospital | 176 (74.9) | 28 (15.9) | 148 (84.1) | 1.00 | … | … | … |
| Health center | 59 (25.1) | 11 (18.6) | 48 (81.4) | 1.21 (.56–2.61) | .62 | … | … |
| Any comorbid condition at baseline | |||||||
| Yes | 92 (39.2) | 9 (9.8) | 83 (90.2) | 1.00 | … | … | 1.00 |
| No | 143 (60.8) | 30 (20.9) | 113 (79.0) | 2.45 (1.10–5.43) | .03b | 1.46 (.53–3.97) | .46 |
| Functionality status | |||||||
| Functional | 187 (79.6) | 32 (17.1) | 155 (82.9) | 1.21 (.49–2.94) | .68 | … | … |
| Nonfunctional | 48 (20.4) | 7 (14.6) | 41 (85.4) | 1.00 | … | … | … |
| Tuberculosis history | |||||||
| Yes | 40 (17.0) | 7 (17.5) | 33 (82.5) | 1.00 | … | … | … |
| No | 195 (82.9) | 32 (16.4) | 163 (83.6) | 0 .9 (.37–2.27) | .87 | … | … |
| INH eligibility | |||||||
| Yes | 170 (87.2) | 28 (16.5) | 142 (83.5) | 1.04 (.33–3.24) | .95 | … | … |
| No | 25 (12.8) | 4 (16.0) | 21 (84.0) | 1.00 | … | … | … |
| Cotrimoxazole prophylaxis | |||||||
| Yes | 148 (62.9) | 27 (18.2) | 121 (81.8) | 1.39 (.67–2.92) | .38 | … | … |
| No | 87 (37.0) | 12 (13.8) | 75 (86.2) | 1.00 | … | … | … |
| WHO clinical stage | |||||||
| I | 131 (55.7) | 33 (25.2) | 98 (74.8) | 5.5 (2.21–13.72) | <.001b | 3.93 (1.34–11.57) | .01b |
| II–IV | 104 (44.3) | 6 (5.8) | 98 (94.2) | 1.00 | … | … | >.99 |
| Same-day ART initiation | |||||||
| Yes | 171 (72.8) | 32 (18.7) | 139 (81.3) | 1.87 (.78–4.49) | .16 | 1.37 (.52–3.58) | .51 |
| No | 64 (27.2) | 7 (10.9) | 57 (89.1) | 1.00 | … | … | >.99 |
| History of substance use | |||||||
| Yes | 83 (35.3) | 16 (19.3) | 67 (80.7) | 1.34 (.66–2.70) | .42 | … | … |
| No | 152 (64.7) | 23 (15.1) | 129 (84.9) | 1.00 | … | … | … |
| Baseline VL category, copies/mL | |||||||
| ≤1000 | 72 (30.6) | 22 (30.6) | 50 (69.4) | 5.61 (1.8–17.4) | .003b | 3.67 (1.09–12.36) | .04b |
| 1001–10 000 | 51 (21.7) | 7 (13.7) | 44 (86.3) | 2.03 (.56–7.39) | .28 | 1.37 (.34–5.38) | .65 |
| 10 001–100 000 | 57 (24.3) | 6 (10.5) | 51 (89.5) | 1.5 (.39–5.63) | .55 | 1.38 (.35–5.44) | .65 |
| >100 000 | 55 (23.4) | 4 (7.3) | 51 (92.7) | 1.00 | … | … | >.99 |
| Baseline body weight, mean (SD), kg | 53.6 (11.9) | 58.5 (9.0) | 52.6 (12.2) | 1.05 (1.01–1.08) | .006b | 1.04 (1.01–1.07) | .02b |
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; COR, crude odds ratio; INH, isoniazid; LTFU, loss to follow-up; SD, standard deviation; VL, viral load; WHO, World Health Organization.
aData represent no. (%) of participants unless otherwise identified as mean (SD).
bSignificant at P < .05.